DK1027365T3 - Antitumor-uridinanaloger - Google Patents
Antitumor-uridinanalogerInfo
- Publication number
- DK1027365T3 DK1027365T3 DK98958451T DK98958451T DK1027365T3 DK 1027365 T3 DK1027365 T3 DK 1027365T3 DK 98958451 T DK98958451 T DK 98958451T DK 98958451 T DK98958451 T DK 98958451T DK 1027365 T3 DK1027365 T3 DK 1027365T3
- Authority
- DK
- Denmark
- Prior art keywords
- substituted
- sugar
- alkoxy
- alkyl
- unsubstituted
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 229910003204 NH2 Inorganic materials 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010022394 Threonine synthase Proteins 0.000 abstract 1
- 102000006601 Thymidine Kinase Human genes 0.000 abstract 1
- 108020004440 Thymidine kinase Proteins 0.000 abstract 1
- 102000005497 Thymidylate Synthase Human genes 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- -1 uridine analogue compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nuclear Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6358797P | 1997-10-30 | 1997-10-30 | |
| PCT/US1998/023109 WO1999023104A2 (en) | 1997-10-30 | 1998-10-30 | Antitumour uridine analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1027365T3 true DK1027365T3 (da) | 2005-05-30 |
Family
ID=22050193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98958451T DK1027365T3 (da) | 1997-10-30 | 1998-10-30 | Antitumor-uridinanaloger |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1027365B1 (da) |
| JP (2) | JP2001522034A (da) |
| AT (1) | ATE287414T1 (da) |
| AU (1) | AU758426B2 (da) |
| CA (1) | CA2307002C (da) |
| DE (1) | DE69828702T2 (da) |
| DK (1) | DK1027365T3 (da) |
| ES (1) | ES2236962T3 (da) |
| WO (1) | WO1999023104A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999008110A1 (en) | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
| IL137164A0 (en) | 1998-01-23 | 2001-07-24 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| CN1390227A (zh) * | 1999-07-22 | 2003-01-08 | 新生物生物公司 | 酶催化的治疗活化 |
| KR20020059341A (ko) | 1999-07-22 | 2002-07-12 | 뉴바이오틱스 인코퍼레이티드 | 치료법-내성 종양의 치료 방법 |
| US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CZ301182B6 (cs) | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
| DE01974666T1 (de) * | 2000-10-06 | 2005-05-04 | Inst Of Whole Body Metabolism | Zweidimensional quantifiziertes bildverfahren zur unterscheidung und quantifizierung von überwachsendem gewebe oder dergleichen |
| EP1359921A4 (en) | 2001-01-19 | 2006-09-06 | Newbiotics Inc | METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
| GB0115927D0 (en) * | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
| WO2003102579A2 (fr) * | 2002-05-31 | 2003-12-11 | Commissariat A L'energie Atomique | Methode de criblage de banques de molecules radioactives et ses applications |
| WO2004002422A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| ES2624353T3 (es) | 2002-11-15 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae |
| RU2005121904A (ru) | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| EP2348131A1 (en) * | 2010-01-22 | 2011-07-27 | Institut Curie | Low levels of cytidine deaminase as a marker for genetic predisposition to develop cancer |
| JP2014062054A (ja) * | 2012-09-20 | 2014-04-10 | Gyoseiin Genshino Iinkai Kakuno Kenkyusho | よう素−１２３標記チミン類似物［１２３Ｉ］−ＩａｒａＵのプローブ |
-
1998
- 1998-10-30 ES ES98958451T patent/ES2236962T3/es not_active Expired - Lifetime
- 1998-10-30 DK DK98958451T patent/DK1027365T3/da active
- 1998-10-30 AT AT98958451T patent/ATE287414T1/de active
- 1998-10-30 AU AU14495/99A patent/AU758426B2/en not_active Ceased
- 1998-10-30 WO PCT/US1998/023109 patent/WO1999023104A2/en not_active Ceased
- 1998-10-30 DE DE69828702T patent/DE69828702T2/de not_active Expired - Lifetime
- 1998-10-30 JP JP2000518974A patent/JP2001522034A/ja active Pending
- 1998-10-30 EP EP98958451A patent/EP1027365B1/en not_active Expired - Lifetime
- 1998-10-30 CA CA002307002A patent/CA2307002C/en not_active Expired - Fee Related
-
2009
- 2009-02-19 JP JP2009037204A patent/JP2009108108A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ATE287414T1 (de) | 2005-02-15 |
| EP1027365A2 (en) | 2000-08-16 |
| WO1999023104A3 (en) | 2000-02-10 |
| CA2307002C (en) | 2008-07-29 |
| ES2236962T3 (es) | 2005-07-16 |
| JP2001522034A (ja) | 2001-11-13 |
| DE69828702D1 (de) | 2005-02-24 |
| DE69828702T2 (de) | 2006-05-11 |
| AU1449599A (en) | 1999-05-24 |
| JP2009108108A (ja) | 2009-05-21 |
| AU758426B2 (en) | 2003-03-20 |
| CA2307002A1 (en) | 1999-05-14 |
| EP1027365B1 (en) | 2005-01-19 |
| WO1999023104A2 (en) | 1999-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1027365T3 (da) | Antitumor-uridinanaloger | |
| Meier | cycloSal-pronucleotides-design of chemical Trojan horses | |
| Frieden et al. | Adenosine deaminase and adenylate deaminase: comparative kinetic studies with transition state and ground state analog inhibitors | |
| Borchardt et al. | Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 1. Modification of the amino acid portion of S-adenosylhomocysteine | |
| JP6163193B2 (ja) | 置換されたヌクレオチドアナログ | |
| Miller et al. | Synthesis and biological activity of some 2'derivatives of adenosine 3', 5'-cyclic phosphate | |
| CA2502109A1 (en) | 4'-c-substituted-2-haloadenosine derivative | |
| FI2604620T4 (fi) | Modifioituja fluorinoituja nukleosidianalogeja | |
| MX167702B (es) | Composicion farmaceutica anti-retroviral de 3'azid-2',3'-dideoxiuridina y metodo para elaborarla | |
| US20100062995A1 (en) | Transition state structure of human 5'methylthioadenosine phosphorylase | |
| BR0011521B8 (pt) | compostos nucleósidos de purina de 4 -c-etinila | |
| ATE196912T1 (de) | Propargylethoxyamino nucleotide | |
| NZ513402A (en) | Novel nucleosides and oligonucleotide analogues | |
| Pugh et al. | Inhibition of Newcastle disease virion messenger RNA (guanine-7-)-methyltransferase by analogs of S-adenosylhomocysteine | |
| Zatorski et al. | Potent inhibitors of human inosine monophosphate dehydrogenase type II. fluorine-substituted analogs of thiazole-4-carboxamide adenine dinucleotide | |
| van Wijk et al. | Lipid conjugates of antiretroviral agents: release of antiretroviral nucleoside monophosphates by a nucleoside diphosphate diglyceride hydrolase activity from rat liver mitochondria | |
| BR9915555A (pt) | Composto, composição e uso de ß - l- (2' ou 3' -azido) - 2', 3' -didesóxi -5-flúor citosina para o tratamento de infecção por vìrus de hepatite b | |
| ES2164869T3 (es) | Conjugados lipidos especificos de nucleosidos-difosfato y su uso como medicamentos. | |
| BR0016162A (pt) | Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos | |
| BR9916849A (pt) | Análogos de nucleosìdeos antivirais | |
| Kappler et al. | Approaches to isozyme-specific inhibitors. 17. Attachment of a selectivity-inducing substituent to a multisubstrate adduct. Implications for facilitated design of potent, isozyme-selective inhibitors | |
| Pankiewicz et al. | The Chemistry of Nicotinamide Adenine Dinucleotide (NAD) Analogues Containing C-Nucleosides Related to Nicotinamide Riboside [1] | |
| Shoshani et al. | Enzymatic Synthesis of Unlabeled and β-32P-labeled β-l-2′, 3′-Dideoxyadenosine-5′-triphosphate as a Potent Inhibitor of Adenylyl Cyclases and Its Use as Reversible Binding Ligand | |
| Velanguparackel et al. | Synthesis, anti-HIV and cytostatic evaluation of 3′-deoxy-3′-fluorothymidine (FLT) pro-nucleotides | |
| Meier | cycloSAL-PRONUCLEOTIDES-DESIGN OF THE CONCEPT |